Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test
Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approved by regulators. Moderna and Merck are developing a treatment using an mRNA-based cancer…
Moderna's shares more than doubled on Wednesday following the announcement of initial results from a study on an experimental cancer treatment. The treatment, an mRNA-based cancer vaccine called intismeran, is being developed in collaboration with Merck. This treatment is unique as it would be tailored to individual patients based on specific mutations within their tumors.
The study compared the use of intismeran and Keytruda, an immunotherapy drug from Merck, on melanoma patients against the use of Keytruda alone. The combination resulted in patients living longer without cancer returning or spreading compared to those who received Keytruda alone. However, the exact duration of survival without cancer return or overall survival was not disclosed.
The companies have stated their intention to present the study results at an upcoming international medical meeting. As a result, Moderna's shares surged by over 120% to $140.12 each, while Merck's shares increased by approximately 11%.
Written by urgent.news from Associated Press's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
